Matches in DBpedia 2014 for { ?s ?p Tiagabine (/taɪˈæɡəbiːn/ is an anti-convulsive medication produced by Cephalon and marketed under the brand name Gabitril. The drug was discovered at Novo Nordisk in Denmark in 1988 by a team of chemists and pharmacologists under the general direction of Dr. Claus Bræstrup. An article authored by Dr. Lars J. S. Knutsen describing the design, selection, pharmacology and synthesis of tiagabine was published in the Journal of Medicinal Chemistry in 1993, pulling together the work of the team at Novo Nordisk. The drug was co-developed with Abbott, in a 40/60 cost sharing deal, with Abbott paying a premium for licensing the IP from the Danish company.Abbott did initially embrace the drug enthusiastically after its US launch in 1998, and provided further clinical studies with the goal of gaining FDA approval for monotherapy in epilepsy. However, the senior management at Abbott drew back after realizing that the original deal with Novo would limit the company's financial gain from a monotherapy approval. After a period of co-promotion, Cephalon licensed Tiagabine from Abbott/Novo and now is the exclusive producer. The medication is also utilized in the treatment of panic disorder, as are a few other anticonvulsants.. }
Showing items 1 to 1 of
1
with 100 items per page.
- Tiagabine abstract "Tiagabine (/taɪˈæɡəbiːn/ is an anti-convulsive medication produced by Cephalon and marketed under the brand name Gabitril. The drug was discovered at Novo Nordisk in Denmark in 1988 by a team of chemists and pharmacologists under the general direction of Dr. Claus Bræstrup. An article authored by Dr. Lars J. S. Knutsen describing the design, selection, pharmacology and synthesis of tiagabine was published in the Journal of Medicinal Chemistry in 1993, pulling together the work of the team at Novo Nordisk. The drug was co-developed with Abbott, in a 40/60 cost sharing deal, with Abbott paying a premium for licensing the IP from the Danish company.Abbott did initially embrace the drug enthusiastically after its US launch in 1998, and provided further clinical studies with the goal of gaining FDA approval for monotherapy in epilepsy. However, the senior management at Abbott drew back after realizing that the original deal with Novo would limit the company's financial gain from a monotherapy approval. After a period of co-promotion, Cephalon licensed Tiagabine from Abbott/Novo and now is the exclusive producer. The medication is also utilized in the treatment of panic disorder, as are a few other anticonvulsants.".